Melanie Baird > Blake, Cassels & Graydon LLP > Toronto, Canada > Lawyer Profile

Blake, Cassels & Graydon LLP

Work Department

Litigation & Dispute Resolution


Melanie’s diverse commercial and intellectual property litigation practice encompasses patent, trademark, complex commercial, class actions, product liability, cannabis and technology disputes. Melanie excels at litigating cases in emerging fields. She was counsel in the first biologic and biosimilar drug patent cases in Canada in addition to numerous precedent-setting trials, applications and appeals. She works extensively with life sciences companies on complex litigation of all sorts and is intimately familiar with the business of pharma and biotech. Melanie also has broad experience in the software, tech and social media spaces, dealing with commercial, patent, trademark, copyright and licensing disputes. She leverages her eclectic experience to handle a wide variety of complex commercial disputes, adeptly devising strategic options and navigating cross-border issues. Melanie is sought after for advice on litigation strategy, evaluation and management of IP portfolios, and regulatory issues.


Melanie regularly speaks and teaches on advocacy and IP topics in Canada and the US. She is heavily involved in The Advocates’ Society 10+ Standing Committee. Other memberships include the Ontario and Canadian Bar Associations, the American Bar Association, IPIC and IPO.

Lawyer Rankings

Canada > Intellectual property

(Next Generation Partners)

Melanie BairdBlake, Cassels & Graydon LLP

Adept in portfolio management, a wealth of disputes and the IP elements of corporate transactions, Blake, Cassels & Graydon LLP‘s team is led from Toronto by Chris Hunter, Andrew Skodyn and Melanie Baird. Hunter runs a patent and trademark prosecution practice in addition to his brand protection and portfolio activities, whereas Skodyn is a disputes specialist with considerable knowledge of the biotech, technology and life sciences industries. Baird holds the distinction of serving as counsel in Canada’s first ever biologic patent and biosimilar patent case.